M. YILMAZ, Emre YAŞAR, B.I. ATASOY, E.G. ÖZGÜR, M.D. AYDIN
The Journal of European Internal Medicine Professionals - 2026;4(1):7-12
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide renal protection in patients with diabetes mellitus (DM) and chronic kidney disease (CKD), but comparative real-world data on dapagliflozin and empagliflozin across different renal diagnoses are limited. Method: In this retrospective observational study, 328 adults with DM and/or CKD, including diabetic nephropathy, glomerulonephritis, and heart failure, who received dapagliflozin or empagliflozin for at least 12 months were evaluated. Results: Of 328 patients, 165 received dapagliflozin and 163 received empagliflozin. Among 298 patients with DM, 61.4% achieved >=50% reduction in albuminuria at 12 months, while 86.7% of 30 non-diabetic patients reached this target. There were no significant differences between dapagliflozin and empagliflozin in albuminuria reduction or eGFR decline across diagnostic categories. Conclusion: In this real-world cohort, dapagliflozin and empagliflozin were similarly effective in substantially reducing albuminuria and preserving eGFR in patients with DM, CKD, glomerulonephritis, and heart failure.
